Literature DB >> 23413009

[Transarterial chemoembolisation in hepatocellular carcinoma].

Johannes Petersen1, Benjamin Henninger, Bernhard Glodny, Werner Jaschke.   

Abstract

Hepatocellular carcinoma is one of the most common cause of cancer related death. The present review gives an overview on the loco-regional therapy performed by transarterial chemoembolization (TACE).TACE combines two different therapeutic approaches. First, application of chemotherapeutic agents into tumor's feeding vessels and second, selectively de-arterialization by different particle embolization applicated during angiography. Different chemoembolization agents and techniques are described. The methode is save and less invasive. Side effects range from the postembolization syndrom with nausea, vomiting, fever and abdominal pain up to hepatic insufficiency, which is very rare.The aim of the therapy is control clinical symptoms, prolonge progression free survival, stabilize quality of life and survival. Further indications are bridging therapy prior liver transplantation and TACE is used as a neoadjuvant therapy.Thus, TACE plays a role in the therapy of HCC and indication should be tailored to the individual patient's condition by an interdisciplinary tumor board.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23413009     DOI: 10.1007/s10354-013-0180-x

Source DB:  PubMed          Journal:  Wien Med Wochenschr        ISSN: 0043-5341


  28 in total

Review 1.  Staging and current treatment of hepatocellular carcinoma.

Authors:  Hollins P Clark; W Forrest Carson; Peter V Kavanagh; Coty P H Ho; Perry Shen; Ronald J Zagoria
Journal:  Radiographics       Date:  2005-10       Impact factor: 5.333

2.  Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma undergoing non-surgical therapy: comparison of Okuda, CLIP, and BCLC staging systems in a single Italian centre.

Authors:  A Grieco; M Pompili; G Caminiti; L Miele; M Covino; B Alfei; G L Rapaccini; G Gasbarrini
Journal:  Gut       Date:  2005-03       Impact factor: 23.059

3.  Longitudinal quality of life assessment of patients with hepatocellular carcinoma after primary transarterial chemoembolization.

Authors:  Brandt C Wible; William S Rilling; Peter Drescher; Robert A Hieb; Kia Saeian; Constantine Frangakis; Yong Chen; Daniel Eastwood; Hyun S Kim
Journal:  J Vasc Interv Radiol       Date:  2010-06-04       Impact factor: 3.464

4.  Liver, gastrointestinal, and cardiac toxicity in intermediate hepatocellular carcinoma treated with PRECISION TACE with drug-eluting beads: results from the PRECISION V randomized trial.

Authors:  Thomas J Vogl; Johannes Lammer; Riccardo Lencioni; Katerina Malagari; Anthony Watkinson; Frank Pilleul; Alban Denys; Clara Lee
Journal:  AJR Am J Roentgenol       Date:  2011-10       Impact factor: 3.959

5.  Recurrences of hepatocellular carcinoma following initial remission by transcatheter arterial chemoembolization.

Authors:  Jae Kyun Lee; Young-Hwa Chung; Byung-Cheol Song; Jung Woo Shin; Won-Beom Choi; Soo Hyun Yang; Hyun-Ki Yoon; Kyu-Bo Sung; Yung Sang Lee; Dong Jin Suh
Journal:  J Gastroenterol Hepatol       Date:  2002-01       Impact factor: 4.029

6.  Prognosis of hepatocellular carcinoma: the BCLC staging classification.

Authors:  J M Llovet; C Brú; J Bruix
Journal:  Semin Liver Dis       Date:  1999       Impact factor: 6.115

7.  Bland embolization in patients with unresectable hepatocellular carcinoma using precise, tightly size-calibrated, anti-inflammatory microparticles: first clinical experience and one-year follow-up.

Authors:  Guido Bonomo; Vittorio Pedicini; Lorenzo Monfardini; Paolo Della Vigna; Dario Poretti; Gianluigi Orgera; Franco Orsi
Journal:  Cardiovasc Intervent Radiol       Date:  2009-12-03       Impact factor: 2.740

8.  Changing international trends in mortality rates for liver, biliary and pancreatic tumours.

Authors:  Shahid A Khan; Simon D Taylor-Robinson; Mireille B Toledano; Angus Beck; Paul Elliott; Howard C Thomas
Journal:  J Hepatol       Date:  2002-12       Impact factor: 25.083

Review 9.  The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma.

Authors:  Josep M Llovet; Josep Fuster; Jordi Bruix
Journal:  Liver Transpl       Date:  2004-02       Impact factor: 5.799

10.  Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study.

Authors:  Johannes Lammer; Katarina Malagari; Thomas Vogl; Frank Pilleul; Alban Denys; Anthony Watkinson; Michael Pitton; Geraldine Sergent; Thomas Pfammatter; Sylvain Terraz; Yves Benhamou; Yves Avajon; Thomas Gruenberger; Maria Pomoni; Herbert Langenberger; Marcus Schuchmann; Jerome Dumortier; Christian Mueller; Patrick Chevallier; Riccardo Lencioni
Journal:  Cardiovasc Intervent Radiol       Date:  2009-11-12       Impact factor: 2.740

View more
  2 in total

Review 1.  Hepatocellular carcinoma: Surgeon's view on latest findings and future perspectives.

Authors:  Jan Erik Slotta; Otto Kollmar; Volker Ellenrieder; B Michael Ghadimi; Kia Homayounfar
Journal:  World J Hepatol       Date:  2015-05-28

Review 2.  The role of bridging therapy in hepatocellular carcinoma.

Authors:  Roberto Galuppo; Angie McCall; Roberto Gedaly
Journal:  Int J Hepatol       Date:  2013-12-19
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.